Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Weighted Average and Diluted) (2021 - 2025)

Cyclerion Therapeutics (CYCN) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.34 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 24.17% year-over-year to -$0.34; the TTM value through Sep 2025 reached -$0.34, up 24.17%, while the annual FY2023 figure was $3.14, 410.41% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.34 in Q3 2025 per CYCN's latest filing, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $5.86 in Q3 2023 and bottomed at -$4.84 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.2, with a median of -$0.31 recorded in 2022.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 2542.19% in 2023, down 1461.29% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.37 in 2021, then skyrocketed by 56.32% to -$0.16 in 2022, then soared by 3763.28% to $5.86 in 2023, then plummeted by 96.6% to $0.2 in 2024, then plummeted by 269.84% to -$0.34 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.34 in Q3 2025, -$0.54 in Q2 2025, and -$0.57 in Q1 2025.